Outcome of Idiopathic Macular Hole

The purpose of this study is to evaluate the role of cataract surgery and cystoid macular edema (CME) on reopening of idiopathic macular holes (IMH).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Idiopathic Macular Hole Cataract Edema Eye Diseases Lens Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ophthalmology Unit CHU Dijon

Dijon, Burgundy, 21000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with with stage 2, 3, or 4 Idiopathic Macular Hole after successful Idiopathic Macular Hole repair

Exclusion criteria

All patients without stage 2, 3, or 4 Idiopathic Macular Hole repair

Treatment and study plan

Primary outcomes

Long-term outcome of idiopathic macular hole surgery

Time frame: 37 months

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire Dijon

Other

Registry information

Official study title

Long-term Outcome of Idiopathic Macular Hole Surgery

Important dates

Study start: 2002
Study completion: 2005
First posted: Jul 17, 2009
Registry last updated: Jul 17, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed